Pliant Therapeutics, Inc. (PLRX) has begun its FORTIFY Phase 1b indication‑expansion trial by dosing the first patient with its lead oncology candidate, PLN‑101095, an oral dual integrin αvβ8/αvβ1 inhibitor. The trial combines PLN‑101095 with the checkpoint inhibitor pembrolizumab in patients whose advanced or metastatic solid tumors have become refractory to prior checkpoint therapy.
The FORTIFY study enrolls three cohorts—non‑small cell lung cancer, clear cell renal cell carcinoma, and tumors with high tumor mutational burden. Participants receive 1,000 mg of PLN‑101095 twice daily for 14 days as monotherapy, after which pembrolizumab is added. The design allows the team to assess safety, tolerability, pharmacokinetics, and early anti‑tumor activity in a larger, more diverse population. Interim data are slated for release in 2027.
The decision to expand into Phase 1b follows encouraging results from the company’s earlier Phase 1 program. In December 2025, the company reported that 4 of 10 heavily pre‑treated patients achieved objective responses—one complete response and three partial responses—demonstrating the drug’s potential to overcome TGF‑β–mediated immunosuppression. Those findings, presented at the AACR 2026 Annual Meeting, provided the clinical rationale for the current expansion.
CEO Bernard Coulie said, 'We are pleased to announce this milestone for the FORTIFY trial and the expansion into solid tumor cohorts that we believe are supported by PLN‑101095's mechanism of action.' He added, 'As a leader in integrin drug development, we look forward to exploring the full potential of this novel drug candidate.' The company’s strategy hinges on the hypothesis that blocking integrin‑mediated TGF‑β activation will sensitize resistant tumors to checkpoint blockade, potentially broadening the benefit of existing therapies.
Pliant remains a clinical‑stage biopharmaceutical with a market capitalization of roughly $75 million and a negative EBITDA. The company’s cash runway extends into the second half of 2028, giving it time to evaluate the 2027 interim data before pursuing later‑stage studies. While the company has not yet released financial guidance tied to the trial, the expansion signals confidence in the pipeline and may influence future funding or partnership opportunities.
No immediate market reaction or analyst commentary has been reported following the announcement. Investors and stakeholders will be watching the 2027 interim data for signals of safety and early efficacy that could shape the company’s trajectory and valuation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.